Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity.

Eiler WJA 2nd, Gleason SD, Smith JL, Witkin JM.

Pharmacol Biochem Behav. 2019 Aug;183:72-79. doi: 10.1016/j.pbb.2019.06.005. Epub 2019 Jun 14.

PMID:
31202811
2.

Microporous polysaccharide hemosphere efficacy and safety in primary total knee arthroplasty.

Gleason S, Mehl D, Payne W, Parry S, Stein AB.

J Orthop. 2018 Dec 6;16(1):19-24. doi: 10.1016/j.jor.2018.11.006. eCollection 2019 Jan-Feb.

PMID:
30765929
3.

Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice.

Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM.

Behav Brain Res. 2019 Mar 15;360:270-278. doi: 10.1016/j.bbr.2018.12.019. Epub 2018 Dec 10.

PMID:
30543903
4.

Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia.

Maxwell J, Gleason SD, Falcone J, Svensson K, Balcer OM, Li X, Witkin JM.

Behav Brain Res. 2019 Feb 1;359:467-473. doi: 10.1016/j.bbr.2018.11.019. Epub 2018 Nov 22.

PMID:
30471311
5.

Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies.

Witkin JM, Shenvi RA, Li X, Gleason SD, Weiss J, Morrow D, Catow JT, Wakulchik M, Ohtawa M, Lu HH, Martinez MD, Schkeryantz JM, Carpenter TS, Lightstone FC, Cerne R.

Biochem Pharmacol. 2018 Sep;155:61-70. doi: 10.1016/j.bcp.2018.06.022. Epub 2018 Jun 22.

6.

Vessel scaling in evergreen angiosperm leaves conforms with Murray's law and area-filling assumptions: implications for plant size, leaf size and cold tolerance.

Gleason SM, Blackman CJ, Gleason ST, McCulloh KA, Ocheltree TW, Westoby M.

New Phytol. 2018 Jun;218(4):1360-1370. doi: 10.1111/nph.15116. Epub 2018 Mar 30.

7.

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats.

Cowen SL, Phelps CE, Navratilova E, McKinzie DL, Okun A, Husain O, Gleason SD, Witkin JM, Porreca F.

Pain. 2018 Jul;159(7):1403-1412. doi: 10.1097/j.pain.0000000000001226.

8.

Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice.

Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM.

Psychopharmacology (Berl). 2018 Apr;235(4):1151-1161. doi: 10.1007/s00213-018-4832-9. Epub 2018 Jan 26.

PMID:
29374303
9.

Efficacy of Intravenous Acetaminophen for Postoperative Analgesia in Primary Total Knee Arthroplasty.

Huang PS, Gleason SM, Shah JA, Buros AF, Hoffman DA.

J Arthroplasty. 2018 Apr;33(4):1052-1056. doi: 10.1016/j.arth.2017.10.054. Epub 2017 Nov 10.

PMID:
29174762
10.

Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611).

Witkin JM, Schober DA, Gleason SD, Catlow JT, Porter WJ, Reel J, Jin X, Hobbs J, Gehlert D, Gernert DL, Gardinier KM, Kato AS, Ping X, Smith JL.

CNS Neurol Disord Drug Targets. 2017;16(10):1099-1110. doi: 10.2174/1871527316666171101132047.

PMID:
29090671
11.

Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors.

Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA.

Neuropharmacology. 2017 Nov;126:257-270. doi: 10.1016/j.neuropharm.2017.07.028. Epub 2017 Jul 28.

PMID:
28757050
12.

Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA.

Pharmacol Res Perspect. 2016 Nov 7;4(6):e00275. doi: 10.1002/prp2.275. eCollection 2016 Dec.

13.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.

Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, Fitzjohn SM, Pasqui F, Wang H, Qian Y, Sher E, Zwart R, Wafford KA, Rasmussen K, Ornstein PL, Isaac JT, Nisenbaum ES, Bredt DS, Witkin JM.

Nat Med. 2016 Dec;22(12):1496-1501. doi: 10.1038/nm.4221. Epub 2016 Nov 7.

PMID:
27820603
14.

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain.

Okun A, McKinzie DL, Witkin JM, Remeniuk B, Husein O, Gleason SD, Oyarzo J, Navratilova E, McElroy B, Cowen S, Kennedy JD, Porreca F.

Pain. 2016 Dec;157(12):2731-2738.

15.

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, Luffer-Atlas D, Desai PV, Swanson S, Burris KD, Ding C, Heinz BA, Need AB, Barth VN, Stephenson GA, Diseroad BA, Woods TA, Yu H, Bredt D, Witkin JM.

J Med Chem. 2016 May 26;59(10):4753-68. doi: 10.1021/acs.jmedchem.6b00125. Epub 2016 Apr 29.

PMID:
27067148
16.

Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8 Through Investigations of TARP γ-8 Null Mice§.

Gleason SD, Kato A, Bui HH, Thompson LK, Valli SN, Stutz PV, Kuo MS, Falcone JF, Anderson WH, Li X, Witkin JM.

CNS Neurol Disord Drug Targets. 2015;14(5):612-26.

PMID:
25921737
17.

Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin.

Witkin JM, Leucke S, Thompson LK, Lynch RA, Ding C, Heinz B, Catlow JT, Gleason SD, Li X.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):498-505.

PMID:
23574162
18.

Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats.

Gleason SD, Yin T, Little SP, Delapp N, Witkin JM.

Behav Pharmacol. 2011 Sep;22(5-6):531-9. doi: 10.1097/FBP.0b013e328349aace.

PMID:
21836463
19.

A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats.

Gleason SD, Witkin JM.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):380-5. Epub 2007 May 24.

PMID:
17583779
20.

Anxiolytic-like effects through a GLUK5 kainate receptor mechanism.

Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM.

Neuropharmacology. 2007 Jun;52(7):1482-7. Epub 2007 Mar 2.

PMID:
17418283

Supplemental Content

Loading ...
Support Center